Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, has filed Prospectus Supplement No. 7, amending and supplementing the original prospectus dated June 28, 2023. This supplement includes information from the company's Form 6-Ks filed on December 29, 2023, and February 23, 2024, with the Securities and Exchange Commission. The supplement pertains to the resale of 291,123,200 ordinary shares represented by 727,808 American Depositary Shares. Additionally, Biodexa announced the appointment of Ann Merchant as a non-executive director effective December 31, 2023. Merchant brings extensive experience from her previous roles at MorphoSys AG, Schreiner Medipharm, and Amgen Inc., and currently serves on the board of Alvotech S.A. In research and development updates, Biodexa reported positive top-line Phase I clinical trial results for MTX110 in treating diffuse midline glioma, with a...Show More

Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, has filed Prospectus Supplement No. 7, amending and supplementing the original prospectus dated June 28, 2023. This supplement includes information from the company's Form 6-Ks filed on December 29, 2023, and February 23, 2024, with the Securities and Exchange Commission. The supplement pertains to the resale of 291,123,200 ordinary shares represented by 727,808 American Depositary Shares. Additionally, Biodexa announced the appointment of Ann Merchant as a non-executive director effective December 31, 2023. Merchant brings extensive experience from her previous roles at MorphoSys AG, Schreiner Medipharm, and Amgen Inc., and currently serves on the board of Alvotech S.A. In research and development updates, Biodexa reported positive top-line Phase I clinical trial results for MTX110 in treating diffuse midline glioma, with a median overall survival of 16.5 months compared to 10.0 months in a comparable cohort. However, a preclinical experiment to demonstrate tolimidone's potential for beta cell proliferation yielded inconclusive results. Despite this, the company plans to proceed with an in vivo preclinical study and preparations for a Phase IIa study of tolimidone in Type 1 diabetes patients.